EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Novel Antibody-Drug-Conjugates in Routine Clinical Practice for the Treatment of Metastatic Breast Cancer: Adherence, Efficacy and Tolerability – Real-World Data from German Breast Centers

Henning Schäffler, Dorothee Jakob, Sophia Huesmann, Kerstin Pfister, Kristina Veselinovic, Fabienne Schochter, Elena Leinert, Visnja Fink, Brigitte Rack, Alexander Englisch, Lea-Louise Volmer, Tobias Engler und 8 weitere

Geburtshilfe und Frauenheilkunde · 01.09.2024 · 84 (09) · 855-865

DOI: 10.1055/a-2375-5194 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Geburtshilfe und Frauenheilkunde, erschienen am 01.09.2024. Verfasst von Henning Schäffler und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The third-generation antibody-drug conjugates (ADC), trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG), recently obtained approval for metastatic breast cancer treatment across various subtypes and therapeutic contexts. This retrospective, multicentric study evaluated real-world tolerability, feasibility and efficacy in a pre-treated, real-world cohort at three major German breast cancer centers. 125 patients treated with T-DXd or SG from November 2020 to June 2023 were included (T-DXd: 77 patients; SG: 48 patients). The median treatment duration was 6.0 months for T-DXd and 3.5 months for SG therapy, with a median follow-up duration of 10.4 months for T-DXd (95% CI: 8.4–11.6) and 11.8 months for SG (95% CI: 8.0–14.4). Severe neutropenia (CTC ≥ III°) occurred in 33.3% during SG therapy, with a numerical reduction observed following primary, prophylactic use of G-CSF. T-DXd-associated pneumonitis occurred in 8 out of 77 patients (10.4 %). Median progression-free survival (mPFS) was 8.6 months (95% CI: 5.8–12.4) with T-DXd (HER2+: 10.8; HER2-low: 4.7) and 4.9 months (95% CI: 2.8–6.3) with SG (TNBC 4.9; HR+/HER2−: not reached). Median overall survival (OS) was 23.8 months (95% CI: 16.1–not estimable) with T-DXd (HER2+: 27.1; HER2-low: not reached), and 12.4 months (95% CI: 8.7–not estimable) with SG therapy (TNBC: 12.4, HR+/HER2−: not reached). 95.7% of the protocol-specified, therapeutic dose was administered for T-DXd and 89.6% for SG. Overall, this indicates good feasibility, tolerability, and effectiveness of ADC therapies in the real-world setting.

Schlagwörter

Stichwörter der Autor:innen

ADCsbreast canceroncologyreal-world evidencesacituzumab govitecansystemic therapytrastuzumab deruxtecan

Autor:innen und Institutionen

  • Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
  • Department of Obstetrics and Gynecology, University of Freiburg, Freiburg, Germany.
  • Department of Women's Health, Tübingen University, Tübingen, Germany.

Zitieren

APA

Schäffler, H., Jakob, D., Huesmann, S., Pfister, K., Veselinovic, K., Schochter, F., Leinert, E., Fink, V., Rack, B., Englisch, A., Volmer, L. L., Engler, T., Frevert, M. L., Juhasz-Böss, I., Brucker, S., Heublein, S., Janni, W., Taran, F. A., Hartkopf, A., & Dannehl, D. (2024). Novel Antibody-Drug-Conjugates in Routine Clinical Practice for the Treatment of Metastatic Breast Cancer: Adherence, Efficacy and Tolerability – Real-World Data from German Breast Centers. Geburtshilfe und Frauenheilkunde, 84(09), 855-865. https://doi.org/10.1055/a-2375-5194

Vancouver

Schäffler H, Jakob D, Huesmann S, Pfister K, Veselinovic K, Schochter F, et al. Novel Antibody-Drug-Conjugates in Routine Clinical Practice for the Treatment of Metastatic Breast Cancer: Adherence, Efficacy and Tolerability – Real-World Data from German Breast Centers. Geburtshilfe und Frauenheilkunde. 2024;84(09):855-865. doi:10.1055/a-2375-5194

BibTeX
@article{Schffler2024,
  author = {Schäffler, Henning and Jakob, Dorothee and Huesmann, Sophia and Pfister, Kerstin and Veselinovic, Kristina and Schochter, Fabienne and Leinert, Elena and Fink, Visnja and Rack, Brigitte and Englisch, Alexander and Volmer, Lea-Louise and Engler, Tobias and Frevert, Marie Louise and Juhasz-Böss, Ingolf and Brucker, Sara and Heublein, Sabine and Janni, Wolfgang and Taran, Florin-Andrei and Hartkopf, Andreas and Dannehl, Dominik},
  title = {Novel Antibody-Drug-Conjugates in Routine Clinical Practice for the Treatment of Metastatic Breast Cancer: Adherence, Efficacy and Tolerability – Real-World Data from German Breast Centers},
  journal = {Geburtshilfe und Frauenheilkunde},
  year = {2024},
  volume = {84},
  number = {09},
  pages = {855--865},
  doi = {10.1055/a-2375-5194}
}
Kostenlos starten →